Posts tagged BRCA2
In conversation with Lloyd Segal of Repare

As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a leading healthcare investment firm with a hands-on approach to company building. Repare is developing precision oncology drugs that target specific vulnerabilities of tumor cells...

Read More
In conversation with Heather Morehouse Ettinger

As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and patent counseling and procurement in the biotechnology and pharmaceutical fields. She regularly handles domestic and international patent portfolios, and due diligence studies for clients, including major corporations and research institutes, and regularly counsels in Hatch-Waxman issues. Dr. Ettinger has a background in recombinant molecular biology, pharmaceutical formulations, genetically modified plants, enzyme and other large molecule technology and small molecule chemistry. She earned her J.D., cum laude, from Fordham University School of Law and her Ph.D. in biological and biomedical sciences from Harvard University. Dr. Ettinger is admitted to practice in New York and New Jersey, and before the U.S. District Court for the Southern District of New York. She is also a registered patent attorney with the U.S. Patent and Trademark Office (USPTO) and was recently selected as a “rising star” by New York Metro Super Lawyers. In this interview with BioTuesdays.com, Dr. Ettinger touches on a broad range of subjects dealing with life sciences IP.

Read More